tiprankstipranks
Advertisement
Advertisement
Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
PremiumRatingsBuy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst
1M ago
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
Premium
Company Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
1M ago
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw
2M ago
SAB Biotherapeutics announces common stock offering, no amount given
PremiumThe FlySAB Biotherapeutics announces common stock offering, no amount given
3M ago
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
Premium
The Fly
SAB Biotherapeutics price target raised to $14 from $12 at Chardan
3M ago
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
Premium
Company Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
3M ago
SAB Biotherapeutics initiated with a Buy at UBS
PremiumThe FlySAB Biotherapeutics initiated with a Buy at UBS
5M ago
Aligos Therapeutics initiated with a Buy at UBS
Premium
The Fly
Aligos Therapeutics initiated with a Buy at UBS
5M ago
SAB Biotherapeutics appoints David Zaccardelli as board chair
Premium
The Fly
SAB Biotherapeutics appoints David Zaccardelli as board chair
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100